{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:33:22Z","timestamp":1774445602800,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced cell therapies often face high parameter uncertainty at launch, prompting calls to collect further data about long-term effectiveness and safety. However, the value of collecting these data to support resource allocation decision-making is not known. Therefore, this study aimed to appraise all published value of information analyses for advanced cell therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review (PROSPERO: CRD42023446874) identified value of information analyses for advanced cell therapies between inception and 14 May 2025 (databases: Medline; Embase). Included studies reported the expected value of perfect information (EVPI), expected value of partial perfect information (EVPPI), expected value of sample information (EVSI) or expected net benefit of sampling (ENBS). Study design and value of information results were summarised in a narrative synthesis. Quality of reporting was assessed using the Consolidated Health Economic Evaluation Reporting Standards Value of Information (CHEERS-VOI) checklist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three published value of information analyses were identified: tisagenlecleucel for relapsed\/refractory acute lymphoblastic leukemia; tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma, and tumor infiltrating lymphocyte cell therapy for advanced melanoma. The beneficiary populations were 6, 36, and 400 individuals per year, respectively. All studies reported EVPI; two studies reported EVPPI. Estimated base case population EVPI was: \u20ac314,455, \u20ac0, and \u20ac2,250,000, respectively. Estimated EVPPI indicated that input parameters for survival extrapolations were the most valuable targets for further research specifically during scenario analyses that explored a lower cost of treatment acquisition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Value of information analyses will help decision-makers, analysts, and manufacturers understand whether long-term data collection is worthwhile to reduce decision uncertainty for advanced cell therapies at launch. Current estimates indicated that the value of further research is likely to be low. The value of collecting additional data will likely increase if future advanced cell therapies are priced such that their corresponding incremental cost-effectiveness ratio aligns with a relevant cost-effectiveness threshold and if they are indicated for larger beneficiary populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13561-026-00728-w","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:23:16Z","timestamp":1771312996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value of information analyses for advanced cell therapies: a systematic review"],"prefix":"10.1186","volume":"16","author":[{"given":"Alexander","family":"Heaps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Gavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"6","key":"728_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jval.2019.03.014","volume":"22","author":"C Quinn","year":"2019","unstructured":"Quinn C, Young C, Thomas J, Trusheim M, the MIT NEWDIGS FoCUS Writing Group. Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system. Value Health. 2019;22(6):621\u20136.","journal-title":"Value Health"},{"issue":"1","key":"728_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"728_CR3","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","volume":"31","author":"D Chancellor","year":"2023","unstructured":"Chancellor D, Barrett D, Nguyen-Jatkoe L, Millington S, Eckhardt F. The state of cell and gene therapy in 2023. Mol Ther. 2023;31(12):3376\u201388.","journal-title":"Mol Ther"},{"issue":"2","key":"728_CR4","doi-asserted-by":"publisher","first-page":"e10214","DOI":"10.1002\/btm2.10214","volume":"6","author":"LL Wang","year":"2021","unstructured":"Wang LL, Janes ME, Kumbhojkar N, et al. Cell therapies in the clinic. Bioeng Transl Med. 2021;6(2):e10214.","journal-title":"Bioeng Transl Med"},{"issue":"12","key":"728_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41434-019-0074-7","volume":"27","author":"K Elverum","year":"2020","unstructured":"Elverum K, Whitman M. Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine. Gene Ther. 2020;27(12):537\u201344.","journal-title":"Gene Ther"},{"issue":"7","key":"728_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","volume":"21","author":"R Hettle","year":"2017","unstructured":"Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1\u2013204.","journal-title":"Health Technol Assess"},{"issue":"8","key":"728_CR7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/14737167.2023.2245138","volume":"23","author":"GW Frederix","year":"2023","unstructured":"Frederix GW, Ham RMT. Gene therapies, uncertainty, and decision-making: thinking about the last Mile at the first step. Expert Rev Pharmacoecon Outcomes Res. 2023;23(8):853\u20136.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"12","key":"728_CR8","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40273-020-00956-w","volume":"38","author":"A Angelis","year":"2020","unstructured":"Angelis A, Naci H, Hackshaw A. Recalibrating health technology assessment methods for cell and gene therapies. PharmacoEconomics. 2020;38(12):1297\u2013308.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"728_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jval.2019.03.012","volume":"22","author":"MF Drummond","year":"2019","unstructured":"Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22(6):661\u20138.","journal-title":"Value Health"},{"issue":"1","key":"728_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12913-023-09494-5","volume":"23","author":"M Drummond","year":"2023","unstructured":"Drummond M, Ciani O, Fornaro G, et al. How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? BMC Health Serv Res. 2023;23(1):484.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"728_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jcyt.2023.03.002","volume":"25","author":"L Ikonomou","year":"2023","unstructured":"Ikonomou L, Cuende N, Forte M, et al. International society for cell & gene therapy position paper: key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products. Cytotherapy. 2023;25(9):920\u20139.","journal-title":"Cytotherapy"},{"issue":"1","key":"728_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jval.2021.07.008","volume":"25","author":"A Gye","year":"2022","unstructured":"Gye A, Goodall S, De Abreu Lourenco R. A systematic review of health technology assessments of chimeric antigen receptor T-Cell therapies in young compared with older patients. Value Health. 2022;25(1):47\u201358.","journal-title":"Value Health"},{"issue":"9","key":"728_CR13","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10198-020-01212-w","volume":"21","author":"D Coyle","year":"2020","unstructured":"Coyle D, Durand-Zaleski I, Farrington J, et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur J Health Econ. 2020;21(9):1421\u201337.","journal-title":"Eur J Health Econ"},{"key":"728_CR14","unstructured":"European Medicines Agency. Advanced therapy medicinal products: Overview. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview. Accessed 10 July 2025."},{"issue":"1","key":"728_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"issue":"23","key":"728_CR16","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1056\/NEJMe2214655","volume":"387","author":"G Coukos","year":"2022","unstructured":"Coukos G. TIL therapy entering the mainstream. N Engl J Med. 2022;387(23):2185\u20136.","journal-title":"N Engl J Med"},{"issue":"8000","key":"728_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"issue":"9","key":"728_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/d41573-020-00099-9","volume":"19","author":"JX Yu","year":"2020","unstructured":"Yu JX, Upadhaya S, Tatake R, Barkalow F, Hubbard-Lucey VM. Cancer cell therapies: the clinical trial landscape. Nat Rev Drug Discov. 2020;19(9):583\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"728_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.stem.2025.03.004","volume":"32","author":"T Deuse","year":"2025","unstructured":"Deuse T, Schrepfer S. Progress and challenges in developing allogeneic cell therapies. Cell Stem Cell. 2025;32(4):513\u201328.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"728_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40273-022-01234-7","volume":"41","author":"SP Gavan","year":"2023","unstructured":"Gavan SP, Wright SJ, Thistlethwaite F, Payne K. Capturing the impact of constraints on the Cost-Effectiveness of cell and gene therapies: A systematic review. PharmacoEconomics. 2023;41(6):675\u201392.","journal-title":"PharmacoEconomics"},{"key":"728_CR21","doi-asserted-by":"publisher","first-page":"e397912","DOI":"10.1200\/EDBK_397912","volume":"43","author":"ERS Cliff","year":"2023","unstructured":"Cliff ERS, Kelkar AH, Russler-Germain DA, et al. High cost of chimeric antigen receptor T-Cells: challenges and solutions. Am Soc Clin Oncol Educ Book. 2023;43:e397912.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"728_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so Far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"728_CR23","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jval.2020.04.1833","volume":"23","author":"RMT ten Ham","year":"2020","unstructured":"ten Ham RMT, Klungel OH, Leufkens HGM, Frederix GWJ. A review of methodological considerations for economic evaluations of gene therapies and their application in literature. Value Health. 2020;23(9):1268\u201380.","journal-title":"Value Health"},{"issue":"9","key":"728_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40273-021-01051-4","volume":"39","author":"JK Ho","year":"2021","unstructured":"Ho JK, Borle K, Dragojlovic N, et al. Economic evidence on potentially curative gene therapy products: A systematic literature review. PharmacoEconomics. 2021;39(9):995\u20131019.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"728_CR25","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1111\/bcp.14275","volume":"87","author":"H Lloyd-Williams","year":"2021","unstructured":"Lloyd-Williams H, Hughes DA. A systematic review of economic evaluations of advanced therapy medicinal products. Br J Clin Pharmacol. 2021;87(6):2428\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"728_CR26","unstructured":"Rutherford M, Lambert P, Sweeting M et al. NICE DSU Technical Support Document 21: Flexible Methods for Survival Analysis. Decision Support Unit. 2020. https:\/\/sheffield.ac.uk\/media\/34188\/download?attachment. Accessed 10 July 2025."},{"issue":"2","key":"728_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","volume":"23","author":"E Fenwick","year":"2020","unstructured":"Fenwick E, Steuten L, Knies S, et al. Value of information analysis for research Decisions-An introduction: report 1 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020;23(2):139\u201350.","journal-title":"Value Health"},{"issue":"3","key":"728_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jval.2011.12.013","volume":"15","author":"S Walker","year":"2012","unstructured":"Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570\u20139.","journal-title":"Value Health"},{"issue":"2","key":"728_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40273-014-0219-x","volume":"33","author":"EC Wilson","year":"2015","unstructured":"Wilson EC. A practical guide to value of information analysis. PharmacoEconomics. 2015;33(2):105\u201321.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"728_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jval.2020.01.004","volume":"23","author":"C Rothery","year":"2020","unstructured":"Rothery C, Strong M, Koffijberg HE, et al. Value of information analytical methods: report 2 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020;23(3):277\u201386.","journal-title":"Value Health"},{"key":"728_CR31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"34","key":"728_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta7340","volume":"7","author":"P Royle","year":"2003","unstructured":"Royle P, Waugh N. Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for clinical excellence appraisal system. Health Technol Assess. 2003;7(34):1\u201351.","journal-title":"Health Technol Assess"},{"key":"728_CR33","unstructured":"US Food & Drug Administration. Approved Cellular and Gene Therapy Products. 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. Accessed 14 May 2025."},{"issue":"3","key":"728_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276\u201382.","journal-title":"Biochem Med (Zagreb)"},{"issue":"10","key":"728_CR35","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jval.2023.06.014","volume":"26","author":"N Kunst","year":"2023","unstructured":"Kunst N, Siu A, Drummond M, et al. Consolidated health economic evaluation reporting Standards - Value of information (CHEERS-VOI): explanation and elaboration. Value Health. 2023;26(10):1461\u201373.","journal-title":"Value Health"},{"issue":"1","key":"728_CR36","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1017\/S0266462322000356","volume":"38","author":"N Carey","year":"2022","unstructured":"Carey N, Leahy J, Trela-Larsen L, McCullagh L, Barry M. Tisagenlecleucel for relapsed\/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis. Int J Technol Assess Health Care. 2022;38(1):e56.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"728_CR37","doi-asserted-by":"publisher","first-page":"2166375","DOI":"10.1080\/20016689.2023.2166375","volume":"11","author":"N Carey","year":"2023","unstructured":"Carey N, Leahy J, Trela-Larsen L, Mc Cullagh L, Barry M. Cost-utility and value of information analysis of tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma in the Irish healthcare setting. J Mark Access Health Policy. 2023;11(1):2166375.","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"728_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1186\/s12885-018-4788-5","volume":"18","author":"VP Ret\u00e8l","year":"2018","unstructured":"Ret\u00e8l VP, Steuten LMG, Geukes Foppen MH, et al. Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. BMC Cancer. 2018;18(1):895.","journal-title":"BMC Cancer"},{"issue":"5","key":"728_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"728_CR40","unstructured":"European Medicines Agency. Kymriah-H-C-4090-P46-011: EPAR - Assessment report. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/kymriah-h-c-4090-p46-011-epar-assessment-report_en.pdf. Accessed 10 July 2025."},{"issue":"36","key":"728_CR41","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I\/Phase II study of blinatumomab in pediatric patients with Relapsed\/Refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"728_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"728_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E van den Neste","year":"2016","unstructured":"van den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transpl. 2016;51(1):51\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"728_CR44","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","volume":"16","author":"MJ Besser","year":"2010","unstructured":"Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16(9):2646\u201355.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"728_CR45","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","volume":"18","author":"LG Radvanyi","year":"2012","unstructured":"Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18(24):6758\u201370.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"728_CR46","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"728_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"3","key":"728_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0272989X13505910","volume":"34","author":"M Strong","year":"2014","unstructured":"Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach. Med Decis Mak. 2014;34(3):311\u201326.","journal-title":"Med Decis Mak"},{"issue":"8","key":"728_CR49","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jval.2024.04.004","volume":"27","author":"K Thavorn","year":"2024","unstructured":"Thavorn K, Thompson ER, Kumar S, et al. Economic evaluations of chimeric antigen receptor T-Cell therapies for hematologic and solid malignancies: A systematic review. Value Health. 2024;27(8):1149\u201373.","journal-title":"Value Health"},{"issue":"3","key":"728_CR50","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jval.2017.10.006","volume":"21","author":"J Lomas","year":"2018","unstructured":"Lomas J, Claxton K, Martin S, Soares M. Resolving the Cost-Effective but unaffordable paradox: estimating the health opportunity costs of nonmarginal budget impacts. Value Health. 2018;21(3):266\u201375.","journal-title":"Value Health"},{"issue":"6","key":"728_CR51","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jval.2019.03.013","volume":"22","author":"A Towse","year":"2019","unstructured":"Towse A, Fenwick E. Uncertainty and cures: Discontinuation, Irreversibility, and Outcomes-Based payments: what is different about a One-Off treatment? Value Health. 2019;22(6):677\u201383.","journal-title":"Value Health"},{"issue":"17\u201318","key":"728_CR52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1089\/hum.2022.056","volume":"33","author":"WAS Hardy","year":"2022","unstructured":"Hardy WAS, Hughes DA. Methods for extrapolating survival analyses for the economic evaluation of advanced therapy medicinal products. Hum Gene Ther. 2022;33(17\u201318):845\u201356.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"728_CR53","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1017\/S0266462322000022","volume":"38","author":"D Jankovic","year":"2022","unstructured":"Jankovic D, Payne K, Kanaan M, Bojke L. Eliciting uncertainty for complex parameters in model-based economic evaluations: quantifying a Temporal change in the treatment effect. Int J Technol Assess Health Care. 2022;38(1):e21.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"728_CR54","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0272989X16639900","volume":"37","author":"C Jackson","year":"2017","unstructured":"Jackson C, Stevens J, Ren S, et al. Extrapolating survival from randomized trials using external data: A review of methods. Med Decis Mak. 2017;37(4):377\u201390.","journal-title":"Med Decis Mak"},{"issue":"2","key":"728_CR55","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.clinthera.2024.11.019","volume":"47","author":"A Greco","year":"2025","unstructured":"Greco A, Frederix GWJ, Hooft L, Ten Ham RMT. A systematic review of challenges and opportunities in the implementation of managed entry agreements for advanced therapy medicinal products. Clin Ther. 2025;47(2):e16\u201326.","journal-title":"Clin Ther"},{"issue":"7","key":"728_CR56","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jval.2018.11.010","volume":"22","author":"X Pouwels","year":"2019","unstructured":"Pouwels X, Grutters JPC, Bindels J, Ramaekers BLT, Joore MA. Uncertainty and coverage with evidence development: does practice Meet theory? Value Health. 2019;22(7):799\u2013807.","journal-title":"Value Health"},{"key":"728_CR57","unstructured":"Desai A, Duran B. Costing Clinical Trials of Advanced Therapy Investigational Medicinal Products using the NIHR interactive Costing Tool - Advice for Pharmacy Sites. 2022. https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2022\/07\/Costing-Clinical-Trials-of-ATIMPs-using-the-interactive-Costing-Tool.pdf. Accessed 10 July 2025."},{"issue":"1","key":"728_CR58","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1017\/S0266462325100391","volume":"41","author":"H Hariram","year":"2025","unstructured":"Hariram H, Gavan SP. Constraints on delivering cell and gene therapies identified during technology appraisal by the National Institute for health and care excellence. Int J Technol Assess Health Care. 2025;41(1):e56.","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"728_CR59","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3111\/13696998.2014.907170","volume":"17","author":"HW Tuffaha","year":"2014","unstructured":"Tuffaha HW, Gordon LG, Scuffham PA. Value of information analysis in healthcare: a review of principles and applications. J Med Econ. 2014;17(6):377\u201383.","journal-title":"J Med Econ"},{"issue":"3","key":"728_CR60","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/0272989X15586552","volume":"36","author":"J Thorn","year":"2016","unstructured":"Thorn J, Coast J, Andronis L. Interpretation of the expected value of perfect information and research recommendations: A systematic review and empirical investigation. Med Decis Mak. 2016;36(3):285\u201395.","journal-title":"Med Decis Mak"},{"issue":"1","key":"728_CR61","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1017\/S0266462325100123","volume":"41","author":"JPC Grutters","year":"2025","unstructured":"Grutters JPC, Bouttell J, Abrishami P, et al. Defining early health technology assessment: Building consensus using Delphi technique. Int J Technol Assess Health Care. 2025;41(1):e34.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"728_CR62","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1017\/S0266462325100147","volume":"41","author":"SP Gavan","year":"2025","unstructured":"Gavan SP. Supporting translation with early health technology assessment: from definition to action. Int J Technol Assess Health Care. 2025;41(1):e39.","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"728_CR63","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jval.2020.02.010","volume":"23","author":"N Kunst","year":"2020","unstructured":"Kunst N, Wilson ECF, Glynn D, et al. Computing the expected value of sample information efficiently: practical guidance and recommendations for four Model-Based methods. Value Health. 2020;23(6):734\u201342.","journal-title":"Value Health"},{"issue":"5","key":"728_CR64","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40258-021-00662-4","volume":"19","author":"H Tuffaha","year":"2021","unstructured":"Tuffaha H, Rothery C, Kunst N, Jackson C, Strong M, Birch S. A review of Web-Based tools for Value-of-Information analysis. Appl Health Econ Health Policy. 2021;19(5):645\u201351.","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"728_CR65","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1177\/0272989X17697692","volume":"37","author":"A Heath","year":"2017","unstructured":"Heath A, Manolopoulou I, Baio G. A review of methods for analysis of the expected value of information. Med Decis Mak. 2017;37(7):747\u201358.","journal-title":"Med Decis Mak"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00728-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:04:23Z","timestamp":1774436663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13561-026-00728-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00728-w","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SPG declares that his institution has received research grants from the National Institute for Health and Care Research (NIHR), Innovate UK, and LifeArc for research into the health economics of cell and gene therapies outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}